UCSF Completes Phase 1/2 Trial of 5-Component HIV Immunotherapy, 7 Out of 10 Patients Achieve Viral Control
Trial Completion and Key Results
The NCT04357821 trial, led by the University of California, San Francisco (UCSF), was a single-arm, open-label Phase 1/2 study targeting functional remission of HIV without antiretroviral therapy (ART). Due to the impact of the COVID-19 pandemic, only 10 participants completed the combination immunotherapy and analytical treatment interruption (ATI), falling short of the original target of 20. According to the registry, the study status is complete. Among the 10 participants, 7 showed low viral set points or complete virological remission after ART discontinuation, with one participant remaining free of viral rebound for over 18 months. However, as a small, non-randomized proof-of-concept study, the results should be interpreted as establishing a biological rationale for follow-up controlled trials rather than confirming the magnitude of therapeutic efficacy.
Composition of the 5-Component Immunotherapy
The regimen included the IL-12 adjuvant DNA vaccine GOVXB-11 targeting conserved HIV Gag regions, the MVA/HIV62B booster, the TLR9 agonist lefitolimod, and the broadly neutralizing antibodies 10-1074 and VRC07-523LS. 10-1074 targets the V3 glycan of the HIV envelope, while VRC07-523LS targets the CD4 binding site. Lefitolimod activates the innate immune receptor TLR9 to stimulate latent reservoirs and antiviral immune responses. Each candidate is an investigational agent without a commercial brand, and the combination therapy itself is in Phase 1/2 and not an FDA-, EMA-, or PMDA-approved treatment. The multi-mechanism approach—using vaccines to prime T-cell responses, antibodies to delay rebound, and immune stimulants to enhance CD8+ T-cell control—complements the limitations of single-modality approaches.
Efficacy Signals and Research Implications
The average time to viral rebound after ART discontinuation was 15 weeks, and 7 participants demonstrated partial or complete post-treatment control, regardless of residual neutralizing antibody concentrations. The low viral set point was associated with strong expansion of CD8+ T-cells activated early after rebound, suggesting that long-term remission may depend more on host immune memory than on antibody exposure alone. These results were published online in December 2025 and are set to appear in Nature in 2026, having passed initial academic validation. However, due to the small sample size of 10 and the selected antibody-sensitive patient cohort, the 70% response rate cannot be directly generalized to the broader HIV patient population.
Market and Competitive Landscape
The current standard of care includes once-daily oral ARTs such as Gilead Sciences (GILD)'s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), which was FDA-approved in February 2018. Long-acting competitors include ViiV Healthcare's Cabenuva (cabotegravir/ritonavir) approved in January 2021 and Gilead's Sunlenca (lenacapavir) approved in December 2022, though all are maintenance therapies aimed at viral suppression rather than functional cure. Competing remission pipelines include the TITAN Phase 2 trial combining 3BNC117, 10-1074, and lefitolimod, and the RIO Phase 2 trial combining 3BNC117-LS and 10-1074-LS. According to Fortune Business Insights, the global HIV therapeutics market is projected to reach USD 38.27 billion in 2025, and treatments that meaningfully extend ART-free periods have the potential to disrupt the value chain of a lifelong treatment-dependent market.
The post-treatment viral control in 7 out of 10 patients and an average rebound delay of 15 weeks provide a rationale for combining vaccines, TLR9 agonists, and broadly neutralizing antibodies in HIV remission research. In the short term, the lack of a control group and the small sample size in the Phase 1/2 trial mean the commercial value assessment is limited, but the results will significantly influence the design of follow-up randomized trials and the identification of predictive biomarkers. In the medium to long term, reducing ART dependency could disrupt the current maintenance therapy landscape dominated by Biktarvy, Cabenuva, and Sunlenca in the USD 38.27 billion HIV therapeutics market in 2025. The study leaves researchers and industry with the challenge of integrating CD8+ T-cell expansion, antibody sensitivity, and viral reservoirs as patient selection criteria, with the comparison to TITAN and RIO Phase 2 trials determining the reproducibility and scalability of the combination therapy.
Source: ClinicalTrials.gov (api_ct)